New drug hope for rare blood disorder that causes anemia in cold weather

NCT ID NCT06067048

Ongoing Disease control Sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests the drug zanubrutinib (Brukinsa) in 25 people with primary cold agglutinin disease, a rare condition where the immune system attacks red blood cells in cold temperatures, causing anemia and poor circulation. The study aims to see if the drug can reduce anemia and cold-related symptoms by targeting the abnormal immune cells. Participants take zanubrutinib capsules daily for up to 36 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: zanubrutinib (Brukinsa)
What this could lead to: If successful, this could offer a new treatment option for cold agglutinin disease that targets both anemia and cold-induced symptoms, potentially improving quality of life.
What could go wrong: This is a small, early-phase trial with only 25 participants, so results may not apply broadly. The drug may cause side effects or fail to improve symptoms significantly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cold agglutinin disease lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LYMPHOMA

Contacts and locations

Locations

AZ Delta

Roeselare, Belgium
Amsterdan UMC ( location AMC)

Amsterdam, Netherlands
Erasusmc

Rotterdam, Netherlands
Haukeland University Hospital Bergen

Bergen, Norway
Odense University Hospital

Odense, Denmark
Oslo University Hospital

Oslo, Norway
Rigshospitalet

Copenhagen, Denmark
UMCG

Groningen, Netherlands
UZ leuven

Leuven, Belgium
st. Olavs Hospital

Trondheim, Norway

More trials for these conditions

Other studies related to the condition(s) this trial covers.